A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease
A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease
|3||Active, not recruiting||
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
† Study has passed its completion date and status has not been verified in more than two years.